FibroGen, Inc. (NASDAQ:FGEN) Short Interest Down 9.2% in July
FibroGen, Inc. (NASDAQ:FGEN) Short Interest Down 9.2% in July
FibroGen, Inc. (NASDAQ:FGEN – Get Rating) saw a large decrease in short interest in the month of July. As of July 31st, there was short interest totalling 4,950,000 shares, a decrease of 9.2% from the July 15th total of 5,450,000 shares. Currently, 5.8% of the company's shares are sold short. Based on an average daily volume of 971,600 shares, the short-interest ratio is presently 5.1 days.
FibroGen,Inc.(納斯達克:FDEN-GET評級)看到空頭股數在7月份大幅下降。截至7月31日,空頭股數共有495萬股,較7月15日的545萬股減少了9.2%。目前,該公司5.8%的股票被賣空。以日均成交量97.16萬股計算,目前短息比率為5.1天。
FibroGen Stock Performance
FibroGen股票表現
Shares of FGEN remained flat at $14.44 during midday trading on Wednesday. 11,717 shares of the stock were exchanged, compared to its average volume of 653,054. The stock has a market cap of $1.35 billion, a price-to-earnings ratio of -6.05 and a beta of 0.87. The company's 50 day simple moving average is $11.91 and its 200 day simple moving average is $11.98. FibroGen has a 52 week low of $7.81 and a 52 week high of $16.91.
在週三午盤交易中,fgen的股價持平於14.44美元。該股成交量為11,717股,而平均成交量為653,054股。該股市值13.5億美元,市盈率為-6.05倍,貝塔係數為0.87。該公司的50日簡單移動均線切入位為11.91美元,200日簡單移動均線切入位為11.98美元。FibroGen的52周低點為7.81美元,52周高位為16.91美元。
FibroGen (NASDAQ:FGEN – Get Rating) last announced its quarterly earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.78) earnings per share for the quarter, topping analysts' consensus estimates of ($0.94) by $0.16. FibroGen had a negative return on equity of 100.51% and a negative net margin of 83.64%. The firm had revenue of $29.81 million for the quarter, compared to the consensus estimate of $36.15 million. During the same quarter in the previous year, the business earned ($1.45) earnings per share. The business's revenue was up 22.3% compared to the same quarter last year. As a group, analysts anticipate that FibroGen will post -3 earnings per share for the current fiscal year.
FibroGen(納斯達克:FDEN-GET評級)上一次公佈季度收益是在8月8日星期一。這家生物製藥公司公佈了該季度每股收益(0.78美元),比分析師普遍預期的(0.94美元)高出0.16美元。FibroGen的淨資產回報率為負100.51%,淨利潤率為負83.64%。該公司本季度營收為2981萬美元,而市場普遍預期為3615萬美元。去年同期,該業務實現每股收益(1.45美元)。與去年同期相比,該業務的收入增長了22.3%。作為一個整體,分析師預計FibroGen將公佈本財年的每股收益為3美元。
Hedge Funds Weigh In On FibroGen
對衝基金對FibroGen的看法
Wall Street Analyst Weigh In
華爾街分析師也加入進來
Several equities analysts have recently issued reports on FGEN shares. Cowen boosted their price target on shares of FibroGen to $14.00 in a report on Monday. The Goldman Sachs Group lowered their target price on FibroGen from $9.00 to $8.00 and set a "sell" rating for the company in a report on Tuesday, May 24th. Finally, StockNews.com cut shares of FibroGen from a "buy" rating to a "hold" rating in a report on Wednesday, August 10th.
幾位股票分析師最近發佈了關於fgen股票的報告。考恩在週一的一份報告中將FibroGen的股價目標上調至14.00美元。在5月24日週二的一份報告中,高盛夫婦將FibroGen的目標價從9.00美元下調至8.00美元,並對該公司設定了“賣出”評級。最後,StockNews.com在8月10日星期三的一份報告中將FibroGen的股票評級從“買入”下調至“持有”。
FibroGen Company Profile
FibroGen公司簡介
(Get Rating)
(獲取評級)
FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.
FibroGen,Inc.是一家生物製藥公司,發現、開發和商業化治療嚴重未得到滿足的醫療需求的療法。該公司正在開發一種口服低氧誘導因子Pro羥基酶小分子抑制劑roxadustat,該藥已在美國、歐洲、中國和日本完成了治療慢性腎臟疾病貧血的第三階段臨牀開發,並在中國完成了治療與骨髓增生異常綜合徵相關的貧血的第二/第三階段臨牀開發。
See Also
另請參閲
- Get a free copy of the StockNews.com research report on FibroGen (FGEN)
- Lowe's Stands Out Amid Q2 Retail Reports
- Agilent Technologies Proves Its Worth VS Illumina
- Target's Results Cap Upside Potential For Retail Stocks
- Are These 3 Video Game Stocks Now In Play?
- 2 Long-Term EV Plays Trading Under $20
- 免費獲取StockNews.com關於FibroGen的研究報告(Fgen)
- Lowe‘s在第二季度零售報告中脱穎而出
- 安捷倫科技對Illumina證明瞭自己的價值
- 塔吉特的業績上限零售類股的上行潛力
- 這3只電子遊戲股票現在還在玩嗎?
- 2輛長期電動汽車的交易價格低於20美元
Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.
接受FibroGen Daily的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對FibroGen和相關公司的最新新聞和分析師評級的每日簡要摘要。